News

Cell therapy company Cartherics has announced that chief operating officer Dr Ian Nisbet will present at the upcoming 2025 BIO International Convention in June.

Noxopharm (ASX:NOX) has been granted approval by the Human Research Ethics Committee for the HERACLES clinical trial following a straightforward review process.

Senior Research Scientist Shanon Ranjit from the Garvan Institute of Medical Research has been named the winner of the Early-Stage Innovation Forum 2025, held as part of the AusMedtech conference in Sydney.

AusBiotech has shared the latest release of Australasian Biotechnology during the biggest week in Australian medtech.

Clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has imaged the first patient in its registrational Phase 3 64Cu-SAR-bisPSMA diagnostic trial in participants with biochemical recurrence (BCR) of prostate cancer.

AusBiotech CEO Rebekah Cassidy and Bellberry's Kylie Sproston spoke at the BioPharmaDispatch conference about Australia's strengths as a location for the life sciences sector and the opportunities to attract more.

Lumos Diagnostics (ASX:LDX) has received confirmation of Medicare reimbursement coverage from an additional Medicare Administrative Contractor, CGS Administrators. 

Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced that the first patient has been dosed in its Phase 2a clinical study of PTX-100.

Atomo Diagnostics (ASX:AT1) has secured another purchase order from the National Association of People with HIV Australia for approximately $450,000 worth of HIV Self-Tests.

Immutep (ASX:IMM) has announced that the investigator-initiated EFTISARC-NEO Phase 2 trial evaluating its eftilagimod alpha with radiotherapy plus MSD's KEYTRUDA (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.

BlinkLab (ASX:BB1) has announced the commencement of the main study phase of its pivotal US-based FDA 510(k) diagnostic trial for its smartphone-based autism diagnostic tool, with the engagement of a significant new clinical site.

Chimeric Therapeutics (ASX:CHM) has announced that the CHM CDH17 clinical trial has advanced to Dose Level 2, following the observation of no safety concerns or off-target effects at Dose Level 1.